Connor, Clark & Lunn Investment Management (CC&L)
RUBY

Connor, Clark & Lunn Investment Management (CC&L)’s Rubius Therapeutics, Inc RUBY Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-353,813
Closed -$301K – 1284
2022
Q2 		$301K Buy
353,813
+296,886
+522% +$498K ﹤0.01% 863
2022
Q1 		$314K Buy
+56,927
New +$362K ﹤0.01% 866

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s RUBY Position: Q3 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Rubius Therapeutics, Inc (RUBY) in Q3 2022, closing a stake of 353,813 shares — an estimated $301K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in RUBY in Q1 2022 and held it in 2 quarters. The position peaked at $314K in Q1 2022. 62 funds tracked by Wall St. Rank hold RUBY as of Q3 2022.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Rubius Therapeutics, Inc position as of Q3 2022 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 353,813 Rubius Therapeutics, Inc shares in Q3 2022, an estimated $301K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Rubius Therapeutics, Inc in Q1 2022 and held it in 2 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Rubius Therapeutics, Inc position peaked at $314K in Q1 2022.
  • 62 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q3 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2022, filed 10 Nov 2022.